Detalhe da pesquisa
1.
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Br J Cancer;
119(2): 153-159, 2018 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29955135
2.
Yale Precision Medicine Tumor Board: reawakening the guardian of the genome.
Lancet Oncol;
23(3): 337-338, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35240081
3.
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.
Lancet Oncol;
22(3): 306-307, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33662283
4.
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.
Lancet Oncol;
21(3): 343-344, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32950226
5.
Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets.
Lancet Oncol;
19(12): 1567-1568, 2018 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32956641
6.
Introduction to the Yale Precision Medicine Tumor Board.
Lancet Oncol;
19(1): 19-20, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29304351
7.
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.
Lancet Oncol;
19(1): 23-24, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29304353
8.
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Nat Commun;
15(1): 4091, 2024 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38750034
9.
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
Cancer Res Commun;
3(6): 1113-1117, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37377610
10.
BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.
Elife;
112022 09 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36098506
11.
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
J Immunother Cancer;
10(2)2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35217573
12.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
J Immunother Cancer;
10(5)2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35577503
13.
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.
JCO Precis Oncol;
5: 466-472, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34994649
14.
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Clin Cancer Res;
27(23): 6366-6375, 2021 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34518310
15.
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Clin Cancer Res;
15(7): 2552-8, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19318484
16.
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.
J Immunother Cancer;
8(2)2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32843490
17.
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors.
Clin Cancer Res;
26(21): 5588-5597, 2020 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32694157
18.
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.
Clin Cancer Res;
25(19): 5808-5817, 2019 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31227504
19.
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Clin Cancer Res;
13(2 Pt 1): 584-90, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17255281
20.
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Cancer Chemother Pharmacol;
60(5): 661-70, 2007 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17216531